Evidence map›Paper›PMID 38462134›Full record

Observational studyJournal of the American Academy of Dermatology2024

Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022.

Nathan C Bahr, Kaitlin Benedict, Mitsuru Toda, Jeremy A W Gold, Shari R Lipner

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American Academy of Dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. The Gut Mycobiome in Inflammatory Bowel Disease: ReframingJournal of fungi (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nathan C BahrDivision of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, Kansas.
Kaitlin BenedictMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Mitsuru TodaMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.
Jeremy A W GoldMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: JGold@cdc.gov.
Shari R LipnerDepartment of Dermatology, Weill Cornell Medicine, New York, New York.
Centers for Disease Control and Prevention · USCornell University · USUniversity of Kansas · US

Funding

Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0M
NINDS NIH HHS K23 NS110470
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Interleukin-17Interleukin-23Invasive Fungal InfectionsPsoriasisAdultAgedFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesUnited StatesInterleukin-17Interleukin-23blastomycosisbrodalumabCandida infectioncandidiasiscoccidioidomycosisCrohn's diseaseesophageal candidiasisguselkumabhistoplasmosisinflammatory bowel diseaseinterleukin-17 inhibitorsinterleukin-23 inhibitorsinvasive fungal infectionixekizumabpsoriasisrisankizumabsecukinumabtildrakizumabustekinumab

Identifiers

PMID38462134
PMCPMC11193621
OpenAlexW4392630635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.